Foundation Medicine prices upsized IPO at $18, above the range

Comment

Shutterstock photo

Foundation Medicine, which offers diagnostic cancer analyses that provide patient specific data for physicians, raised $106 million by offering 5.9 million shares (up from an expected 5.0 million) at $18, above the range of $14 to $16. Foundation Medicine plans to list on the NASDAQ under the symbol FMI. Foundation Medicine initially filed confidentially on 6/24/2013. Goldman Sachs and J.P. Morgan acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com